IRIS Accounts Production v23.2.0.158 06892400 director 1.5.22 30.4.23 30.4.23 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh068924002022-04-30068924002023-04-30068924002022-05-012023-04-30068924002021-04-30068924002021-05-012022-04-30068924002022-04-3006892400ns10:Originalns15:EnglandWales2022-05-012023-04-3006892400ns14:PoundSterlingns10:Original2022-05-012023-04-3006892400ns10:Originalns10:Director12022-05-012023-04-3006892400ns10:Original2022-05-012023-04-3006892400ns10:Original2023-04-3006892400ns10:Originalns10:PrivateLimitedCompanyLtd2022-05-012023-04-3006892400ns10:Originalns10:SmallEntities2022-05-012023-04-3006892400ns10:Originalns10:AuditExemptWithAccountantsReport2022-05-012023-04-3006892400ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-05-012023-04-3006892400ns10:SmallCompaniesRegimeForAccountsns10:Original2022-05-012023-04-3006892400ns10:Originalns10:FullAccounts2022-05-012023-04-3006892400ns10:Original2021-05-012022-04-3006892400ns10:Originalns10:RegisteredOffice2022-05-012023-04-3006892400ns10:Original2022-04-3006892400ns10:Originalns5:CurrentFinancialInstruments2023-04-3006892400ns10:Originalns5:CurrentFinancialInstruments2022-04-3006892400ns5:ShareCapitalns10:Original2023-04-3006892400ns5:ShareCapitalns10:Original2022-04-3006892400ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-04-3006892400ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-04-3006892400ns10:Originalns5:PlantMachinery2022-05-012023-04-3006892400ns10:Originalns5:PlantMachinery2023-04-3006892400ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-3006892400ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-04-30
REGISTERED NUMBER: 06892400 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 April 2023

for

Croptek Bio Ltd

Croptek Bio Ltd (Registered number: 06892400)






Contents of the Financial Statements
for the Year Ended 30 April 2023




Page

Company Information 1

Chartered Certified Accountants' Report 2

Balance Sheet 3

Notes to the Financial Statements 5


Croptek Bio Ltd

Company Information
for the Year Ended 30 April 2023







DIRECTOR: M P Noble





REGISTERED OFFICE: Anglia House
Hamburg Way
North Lynn Industrial Estate
King's Lynn
Norfolk
PE30 2ND





REGISTERED NUMBER: 06892400 (England and Wales)





ACCOUNTANTS: Steve Pye & Co.
Chartered Certified Accountants
Unit 8
Home Farm
Norwich Road
Norwich
Norfolk
NR10 5PQ

Chartered Certified Accountants' Report to the Director
on the Unaudited Financial Statements of
Croptek Bio Ltd

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Croptek Bio Ltd for the year ended 30 April 2023 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/rulebook.

This report is made solely to the director of Croptek Bio Ltd in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Croptek Bio Ltd and state those matters that we have agreed to state to the director of Croptek Bio Ltd in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its director for our work or for this report.

It is your duty to ensure that Croptek Bio Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Croptek Bio Ltd. You consider that Croptek Bio Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Croptek Bio Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Steve Pye & Co.
Chartered Certified Accountants
Unit 8
Home Farm
Norwich Road
Norwich
Norfolk
NR10 5PQ


9 October 2023

Croptek Bio Ltd (Registered number: 06892400)

Balance Sheet
30 April 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 5 890 -

CURRENT ASSETS
Debtors 6 20,090 19,647
Cash at bank and in hand 5,468 4,581
25,558 24,228
CREDITORS
Amounts falling due within one year 7 26,119 23,823
NET CURRENT (LIABILITIES)/ASSETS (561 ) 405
TOTAL ASSETS LESS CURRENT
LIABILITIES

329

405

PROVISIONS FOR LIABILITIES 169 -
NET ASSETS 160 405

CAPITAL AND RESERVES
Called up share capital 2 2
Retained earnings 158 403
160 405

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Croptek Bio Ltd (Registered number: 06892400)

Balance Sheet - continued
30 April 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 October 2023 and were signed by:





M P Noble - Director


Croptek Bio Ltd (Registered number: 06892400)

Notes to the Financial Statements
for the Year Ended 30 April 2023

1. STATUTORY INFORMATION

Croptek Bio Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
In the application of the company's accounting policies, management is required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period to which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are the depreciation charges that are calculated with reference to the useful economic life of fixed assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on reducing balance

Croptek Bio Ltd (Registered number: 06892400)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2023

3. ACCOUNTING POLICIES - continued

Financial instruments
The company enters into basic financial instruments that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties and loans to related parties.

a) Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less impairment losses for bad and doubtful debts.

b) Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand.

c) Impairment of financial assets
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit or loss.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and the best estimate, which is an approximation, of the amount that the company would receive for the asset if it were to be sold at the reporting date.

d) Trade and other creditors
Debt instruments like loans and other accounts payable are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method. Debt instruments that are payable within one year, typically trade payables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an outright short-term loan not at market rate, the financial asset is measured, initially and subsequently, at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Croptek Bio Ltd (Registered number: 06892400)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2023

3. ACCOUNTING POLICIES - continued

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 890
At 30 April 2023 890
NET BOOK VALUE
At 30 April 2023 890

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 17,992 2,484
Amounts owed by participating interests 892 -
Other debtors 1,206 17,163
20,090 19,647

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 12,302 -
Amounts owed to participating interests 5,503 12,149
Taxation and social security 5,271 2,448
Other creditors 3,043 9,226
26,119 23,823